Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has announced that, following a review of the development and commercial portfolios in the primary care business unit, it is terminating Phase III development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder.
Subscribe to our email newsletter
Pfizer said that the decision to terminate these programs will enable the business unit to allocate additional resources to higher-potential development programs as part of its continuing effort to deliver greater value to patients and the company’s shareholders.
After reviewing the results of the first Phase III study for PD 332,334 for the treatment of generalized anxiety disorder (GAD) and the existing data for esreboxetine for the treatment of fibromyalgia, along with current market dynamics, it was considered unlikely that either compound would provide meaningful benefit to patients beyond the current standard of care. Neither compound was terminated due to safety reasons. Pfizer will continue to pursue an indication for Lyrica CV in the treatment of GAD.
Pedro Lichtinger, president and general manager of Pfizer’s primary care business unit, said: In primary care, we continually review our portfolio to ensure we are developing medicines in areas of unmet need and have found significant potential opportunities to bring more value to patients and our company. Our goal is to use our resources efficiently and effectively to continue to deliver medical innovations to the global health community.